Relay Therapeutics (RLAY) Enterprise Value (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Enterprise Value of -$642.1 million for Q1 2026, down 586.39% year-over-year from $132.0 million in Q1 2025, and down 15.79% quarter-over-quarter from -$554.5 million in Q4 2025.
Relay Therapeutics (RLAY) Enterprise Value (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Enterprise Value for 8 consecutive years, with -$642.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 586.39% year-over-year to -$642.1 million; the TTM figure through Mar 2026 stood at -$642.1 million (down 586.39% YoY), while the FY2025 annual figure was -$554.5 million, down 346.16% from the prior year.
- Enterprise Value eased to -$642.1 million in Q1 2026 per RLAY's latest filing, from -$554.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$91.6 million in Q3 2025 and bottomed at -$642.1 million in Q1 2026.
- Historically, Enterprise Value has averaged -$199.7 million across 5 years, with a median of -$145.9 million in 2023.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 58.57% — and 2026, when it tumbled 586.39%.
- Relay Therapeutics' Enterprise Value stood at -$151.8 million in 2022, then climbed by 5.31% to -$143.7 million in 2023, then advanced by 13.53% to -$124.3 million in 2024, then slumped by 346.16% to -$554.5 million in 2025, then declined by 15.79% to -$642.1 million in 2026.
- Business Quant data shows RLAY's Enterprise Value at -$642.1 million in Q1 2026, -$554.5 million in Q4 2025, and -$91.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | -910.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -910.93 Mn |
| Mar 31, 2026 | -642.07 Mn |
| Dec 31, 2025 | -554.52 Mn |
| Sep 30, 2025 | -91.56 Mn |
| Jun 30, 2025 | -113.94 Mn |
| Mar 31, 2025 | -93.54 Mn |
| Dec 31, 2024 | -124.29 Mn |
| Sep 30, 2024 | -152.36 Mn |
| Jun 30, 2024 | -134.13 Mn |
| Mar 31, 2024 | -152.87 Mn |
| Dec 31, 2023 | -143.74 Mn |
| Sep 30, 2023 | -151.33 Mn |
| Jun 30, 2023 | -145.90 Mn |
| Mar 31, 2023 | -161.28 Mn |
| Dec 31, 2022 | -151.79 Mn |
| Sep 30, 2022 | -354.64 Mn |
| Jun 30, 2022 | -107.74 Mn |
| Mar 31, 2022 | -119.45 Mn |
| Dec 31, 2021 | -280.12 Mn |
| Sep 30, 2021 | -228.56 Mn |